➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School

Last Updated: August 9, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,865,211

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,865,211 protect, and when does it expire?

Patent 8,865,211 protects DSUVIA and is included in one NDA.

This patent has sixty-eight patent family members in twelve countries.

Summary for Patent: 8,865,211
Title:Bioadhesive drug formulations for oral transmucosal delivery
Abstract: Bioadhesive drug formulations that adhere to an oral mucosal membrane of a subject are provided together with single dose applicators and devices for delivering the drug formulations to the oral mucosa, and methods for using the same.
Inventor(s): Tzannis; Stelios (Petaluma, CA), Hamel; Larry (Pacific Grove, CA), Palmer; Pamela (San Francisco, CA), Schreck; Thomas (Portola Valley, CA), Poutiatine; Andrew I. (Mill Valley, CA)
Assignee: AcelRx Pharmaceuticals, Inc. (Redwood City, CA)
Application Number:13/595,879
Patent Claim Types:
see list of patent claims
Use; Formulation; Delivery; Device; Dosage form;

Drugs Protected by US Patent 8,865,211

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Acelrx Pharms DSUVIA sufentanil citrate TABLET;SUBLINGUAL 209128-001 Nov 2, 2018 RX Yes Yes   Start Trial   Start Trial TREATMENT OF ACUTE PAIN   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,865,211

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 474564   Start Trial
Canada 2636088   Start Trial
Canada 2636115   Start Trial
Canada 2636119   Start Trial
Canada 2673837   Start Trial
Canada 2673856   Start Trial
Canada 2673880   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.